Get our lovely INSIGHT 2019 conference news

Email address
First Name
Last Name
Interested in InSight 2019

What are you looking for?

<Good_things_happen/> Welcome to Conference

Phenomenology of the ketamine experience, reports from Ketamine Assisted Psychotherapy (KAP)

Ketamine is unique from the known and loved phenethylamines (MDMA), tryptamines (psilocybin), and ergolines (LSD), which tend to exert their effects by interacting with serotonin, dopamine, and/or norepinephrine receptors. Ketamine is classified as a dissociative anesthetic and is listed as a Schedule III drug in the United States. It has a novel mechanism of action as an N-methyl-D-aspartate (NMDA) receptor antagonist. In addition, its effects can be quite different from the more typical entheogens. Due to the dissociation occasioned by ketamine, we believe this supports non-ordinary states of consciousness (NOSC) that are quite unique from NOSC’s produced by other entheogens and this is an important piece of ketamine’s unique healing potential.

Ketamine was discovered in the 1960’s and was primarily used in surgical anesthesia, but soon after, its use by surgeons and anesthesiologists declined due to “emergence phenomena”, described as an “unwanted” side effect of the medicine. As anesthesia wore off, patients often reported travels through a wide range of realities and alternate realms – extraterrestrial civilizations and parallel universes, astrophysical worlds and the animal, botanical, and mineral kingdoms, visits to other countries and historical periods. These reports sometimes alarmed post-surgery teams, but psychedelic therapists and researchers became very interested in this “side effect”. Famed Mexican psychiatrist Salvador Roquet, described it as the “principal fascinating effect” of ketamine rather than an unwanted side effect. The emergence phenomenon is a non-ordinary state of consciousness (NOSC). We believe that healing and transformation can happen through NOSC and we are interested in the relationship of the phenomenological experience of ketamine-induced NOSC to the healing of mental health challenges.

Interest in the use of ketamine for the treatment of depression has grown steadily since Zarate and team published their article in 2006. In March 2019, Janssen received FDA approval for esketamine (brand name Spravato) for treatment of depression, which is bringing more interest to the field and greater acceptance of this extraordinary medicine.

We will discuss the phenomenology of ketamine experiences when used in the context of a therapeutic set and setting. This presentation will focus on the classification and description of reports of subjective experiences of Ketamine-Assisted Psychotherapy (KAP) clients. It is our belief that healing and transformation happens through direct experience and we will highlight the unique qualities of experiential learning under the influence of ketamine. We will also consider whether there may be a direct link between the types of phenomena in the ketamine experience and the depth of psychological healing and the subsequent discovery of meaning and life direction.



September 7th 2019


14:45 - 15:15



Related Events

A new approach to treating depression; a non-profit’s role in advancing the science and regulatory path to approval for psilocybin

In this presentation, Dr. Charles Raison will discuss the unmet medical need in depression treatment, the results of promising academic studies to date, and Usona’s unique role in sponsoring FDA-regulated clinical trials as a nonprofit medical research entity following an Open Science approach to research and drug development.

more details

Therapists versus Healers – Requirements for Training and Personality of Psychedelic Therapists

The requirements for psychedelic therapists’ training is one of the most controversially discussed topics in the field. Which level of formal training does a psychedelic therapist need to go through before she/he can offer a psychedelic-assisted treatment, and to whom? All these questions constitute controversies that need to be debated and decided. But who should have a say in the regulation of the figure of psychedelic therapist? Do future psychedelic therapists have to be medical doctors or psychiatrists (since these are usually […]

more details

Conference tickets

With your ticket you will have access to the whole conference - with keynotes, panels, round tables, posters and daylight social events. We will ask for a small extra fee for the Friday evening social program. The pre-conference workshops have to be booked separately and each workshop needs an individual ticket. By clicking on "Book now" below you also have the option to buy your workshop tickets.

*Reduced fees apply to students, cooperation partners as well as unemployed and retired individuals who have a monthly net income below 840,- €. Proof of status will be required.

THE CONFERENCE IS SOLD OUT! Subscribe to our newsletter to become an early bird for 2021!

Get our lovely INSIGHT 2019 conference news

Email address
First Name
Last Name